Controlled Substances Prescription Regulation

Core Regulatory Requirements

• Clinicians must review the state Prescription Drug Monitoring Program (PDMP) when starting controlled substance therapy and periodically during continuation, ideally before every prescription, or at minimum every 3 months, to identify dangerous combinations and high-risk dosing patterns, as recommended by the American Medical Association 1, 2
• Check PDMP data before each controlled substance prescription to determine if patients are receiving dangerous combinations or high total dosages from multiple prescribers that increase overdose risk, with a strength of evidence categorized as high 1, 2, 3
• Calculate total morphine milligram equivalents (MME) per day when multiple opioid prescriptions are identified to assess cumulative exposure, with a Category B recommendation from the Centers for Disease Control and Prevention 1, 4

Urine Drug Testing Requirements

• Perform urine drug testing before initiating opioid therapy for chronic pain, with a Category B recommendation from the Centers for Disease Control and Prevention 5, 4, 6
• Conduct annual urine drug testing at minimum during ongoing opioid therapy to assess for prescribed medications, other controlled substances, and illicit drugs, with a Category B recommendation from the Centers for Disease Control and Prevention 5, 7, 8

Specific Controlled Substance Classes

• Avoid dosages ≥90 MME/day or carefully justify any decision to titrate to this level, with a strong recommendation from the Centers for Disease Control and Prevention 7, 9
• Exercise increased caution at ≥50 MME/day, carefully reassessing individual benefits versus risks, with a strong recommendation from the Centers for Disease Control and Prevention 7, 9

High-Risk Combinations to Avoid

• Avoid prescribing opioids and benzodiazepines concurrently whenever possible, with a Category A recommendation from the American Medical Association 1, 6, 7, 9, 3
• Offer naloxone when concurrent benzodiazepine and opioid use is present, as this represents increased overdose risk, with a strong recommendation from the Centers for Disease Control and Prevention 7, 9, 3

Special Populations Requiring Enhanced Monitoring

• Elderly patients (≥65 years) require additional caution due to decreased drug clearance, increased CNS depressant sensitivity, and higher fall risk, with a strong recommendation from the American Geriatrics Society 3, 10
• Patients with substance use disorder history require careful consideration of increased risks, with a strong recommendation from the American Society of Addiction Medicine 1, 6, 3

Actions When PDMP Reveals Concerning Patterns

• Discuss PDMP findings with the patient and confirm awareness of additional prescriptions, with a strong recommendation from the American Medical Association 1, 5, 4
• Consider substance use disorder when patterns suggest misuse and discuss concerns directly with the patient, with a strong recommendation from the American Society of Addiction Medicine 1, 5, 4

Critical Pitfalls to Avoid

• Never dismiss patients from practice based on PDMP information alone, as this eliminates opportunities to provide potentially lifesaving interventions, with a strong recommendation from the American Medical Association 1, 5, 6, 8
• Never implement rapid tapers for long-term benzodiazepine users; reduce by 10% per month for use exceeding 1 year, or over several months for use exceeding 6 years, with a strong recommendation from the American Psychiatric Association 8

Controlled Substance Prescribing Guidelines for High-Risk Patients

Special Considerations for Prescribing Controlled Substances

• When prescribing controlled substances to patients with a history of substance abuse, the American Medical Association recommends reviewing both states' Prescription Drug Monitoring Programs (PDMPs) before each prescription to identify dangerous combinations or multiple prescribers 11, 12
• The Centers for Disease Control and Prevention suggests conducting urine drug testing before initiating opioid therapy and at least annually thereafter, with a strength of evidence rated as "strong" 11, 13
• The American College of Physicians recommends implementing a patient-provider agreement outlining informed consent and care plan, with a strength of evidence rated as "moderate" 14, 15
• The National Institute on Drug Abuse advises avoiding concurrent benzodiazepine prescribing whenever possible, with a strength of evidence rated as "high" 11, 13
• The Substance Abuse and Mental Health Services Administration recommends offering naloxone to patients with a history of substance use disorder, as they face increased overdose risk, with a strength of evidence rated as "strong" 11, 12
• A history of substance use disorder is not an absolute contraindication to controlled substances, but requires careful risk-benefit analysis and increased monitoring frequency, according to the American Society of Addiction Medicine 14, 16, 12
• When calculating whether benefits outweigh risks, consider factors such as current engagement in addiction treatment, presence of concurrent benzodiazepine use, total morphine milligram equivalents, and availability of non-opioid alternatives, as recommended by the American Academy of Pain Medicine 14, 16, 13, 15
• If risks outweigh benefits, manage pain with non-controlled alternatives and provide linkages to addiction treatment services, as suggested by the American College of Physicians 14, 16
• Civil liability may occur if patient harm occurs when prescribing controlled substances across state lines without proper authorization, as noted by the American Medical Association 12